The Unmet Medical Need in Epilepsy: The Therapeutic Potential of Potassium Channel Modulators
Friday, December 3, 2021
-
You may need to log in to view video on this page.
The session will begin with a discussion of the unmet medical need for persons with epilepsy. The discussion will then focus on addressing that unmet need by presenting clinical evidence for a novel voltage-gated potassium channel allosteric modulator (Kv7 PAM) as an antiseizure treatment. The second lecture will be an in-depth discussion of the Kv7 mechanism, including its relevance to epilepsy and depression and the implications of receptor subunit-specific drug activity. The third brief lecture will present specific aspects of the Phase 2b clinical trial related to the Kv7 PAM mechanism and electronic diary use in adult focal onset seizures. The final lecture will discuss the general landscape of current and future epilepsy treatment avenues, and the role of Kv7 PAM in rational polypharmacy. Two brief question and answer periods will be incorporated into the program.
Sponsor: Xenon Pharmaceuticals Inc.
Learning Objectives:
Following participation in this activity, participants will be able to:
- Following participation in this conference, learners will know the contributing factors to the unmet medical need in epilepsy, and will be able to recognize and address this treatment gap more readily in their own practices.
- Following participation in this conference, learners will understand the localization of the multiple Kv7 channel subunits and how the association of a drug product for activity at specific subunits can result in benefit or adverse events (or both).
- Following participation in this conference, learners will have an increased knowledge of how to epilepsy treatments can be used together based on their mechanism (rational polypharmacy) including Kv7 PAMs